Clinical trials
Disease trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
434 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 3 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 7 |
| 2010 | 7 |
| 2011 | 11 |
| 2012 | 15 |
| 2013 | 11 |
| 2014 | 8 |
| 2015 | 20 |
| 2016 | 28 |
| 2017 | 41 |
| 2018 | 33 |
| 2019 | 30 |
| 2020 | 33 |
| 2021 | 44 |
| 2022 | 39 |
| 2023 | 54 |
| 2024 | 31 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 434 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 6 |
| Assistance Publique - Hôpitaux de Paris | 5 |
| First Affiliated Hospital Xi'an Jiaotong University | 5 |
| Peking Union Medical College Hospital | 5 |
| RenJi Hospital | 5 |
| Cairo University | 4 |
| Central South University | 4 |
| Changhai Hospital | 4 |
| Fudan University | 4 |
| Hospices Civils de Lyon | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Disease | 434 |
| Lung Neoplasms | 16 |
| Breast Neoplasms | 13 |
| Neoplasms | 11 |
| Prostatic Neoplasms | 11 |
| Pneumonia | 9 |
| COVID-19 | 8 |
| Colorectal Neoplasms | 7 |
| Sepsis | 7 |
| Tuberculosis | 7 |
Trials
Showing 51 to 75 of 434. Each trial links to its page on Pharma Observatory.
334 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.